Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | CDC7 | O00311 | 8/20 | 0.47 |
| ▸ | CDK2 | P24941 | 6/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.47 |
| ▸ | PIM1 | P11309 | 4/20 | 0.47 |
| ▸ | PRKACA | P17612 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | HIPK2 | Q9H2X6 | 4/20 | 0.47 |
| ▸ | MET | P08581 | 4/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.47 |
| ▸ | FLT3 | P36888 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414322 | 0.87 | CDC7 (0.45) | CSF1RKITCDC7CDK2ROCK2 | |
| SCHEMBL1267463 | 0.77 | CSF1R (0.68) | CSF1RKITCDC7CDK2ROCK2 | |
| SCHEMBL1268047 | 0.76 | CSF1R (0.50) | CSF1RKITCDC7CDK2ROCK2 | |
| SCHEMBL413118 | 0.76 | AXL (0.40) | CDC7CDK2ROCK2PIM1PRKACA | |
| SCHEMBL878720 | 0.75 | CSF1R (0.48) | CSF1RKITCDC7CDK2ROCK2 | |
| SCHEMBL878907 | 0.75 | CSF1R (0.78) | CSF1RKITCDC7CDK2ROCK2 | |
| SCHEMBL20086207 | 0.75 | CSF1R (0.56) | CSF1RKITCDC7CDK2ROCK2 | |
| SCHEMBL857484 | 0.75 | CSF1R (0.70) | CSF1RKITCDC7CDK2ROCK2 | |
| SCHEMBL878781 | 0.73 | CSF1R (0.68) | CSF1RKITCDC7CDK2ROCK2 | |
| SCHEMBL857418 | 0.73 | CSF1R (0.65) | CSF1RKITCDC7CDK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9169250-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20140243365-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2014-08-28 | — | — | US | disclosed |
| US-8722702-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130178473-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8461169-B2 | Compounds modulating c-fms and/or c-kit activity | PLEXXIKON INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8404700-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-7947708-B2 | Compounds modulating C-kit activity | PLEXXIKON, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7846941-B2 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090105297-A1 | Compounds Modulating C-Kit Activity | PLEXXIKON INC | 2009-04-23 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-7498342-B2 | Compounds modulating c-kit activity | PLEXXIKON, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1885723-A2 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007013896-A2 | PYRROL (2,3-B) PYRIDINE DERIVATIVES PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20060058339-A1 | Compounds modulating c-kit activity and uses therefor | PLEXXIKON, INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243365-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CSF1R 4/4885KIT 1/4885CDC7 280/4885 |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CSF1R 4/4885KIT 1/4885CDC7 280/4885 |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | CSF1R 4/4885KIT 1/4885CDC7 280/4885 |
| US-20130178473-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CSF1R 4/4885KIT 1/4885CDC7 280/4885 |
| US-20090105297-A1 | Compounds Modulating C-Kit Activity | KIT, CDC7, CDK7 | CSF1R 363/4885KIT 1/4885CDC7 2/4885 |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CSF1R 4/4885KIT 1/4885CDC7 280/4885 |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CSF1R 4/4885KIT 1/4885CDC7 242/4885 |
| US-20060058339-A1 | Compounds modulating c-kit activity and uses therefor | KIT, APC, RET | CSF1R 120/4885KIT 1/4885CDC7 156/4885 |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | KIT, FLT3, FLT1 | CSF1R 7/4885KIT 1/4885CDC7 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.